Navigation Links
ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells

ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS... -- YOKOHAMA, Japan, September 1, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells


YOKOHAMA, Japan, September 1, 2010 /PRNewswire/ -- ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) is pleased to announce a new line of products to be launched in the autumn of 2010, offering neuronal cells derived from human iPS (induced pluripotent stem) cells.

Since April 2009, ReproCELL has been manufacturing iPS cell-derived cardiomyocytes for drug toxicity testing as the world's first drug discovery support business provider founded on iPS cells. The prospective new offering of neuronal cells is the second line of services to be introduced by the company, and is a considerable expansion of their scope of business. ReproCELL will be the first in the world to offer iPS cell derived neuronal cells, and, more specifically, will provide dopaminergic neurons, motor neurons, and cerebral nerves.

ReproCELL's Representative Director and CEO Chikafumi Yokoyama PhD commented, "Despite the constant rise of patients with neurodegenerative disorders such as Alzheimer's and Parkinson's Disease, fundamental therapies are still sought after in this ageing society. Through offering human iPS cell derived neuronal cells to the pharmaceutical industry, we hope to enable more effective screening of various neuroactive therapeutic compounds, thereby contributing to the development of new medicines."

In addition, the company welcomes its new scientific advisor, Professor Sian Harding at the National Heart and Lung Institute, Imperial College London, a leading expert in pluripotent stem-cell derived cardiomyocytes. Through this new collaboration, the company aims to accelerate further research and development in the use of iPS cells in this field.


Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
Breaking Biology News(10 mins):